The primary goal of this joint venture is to develop and commercialise novel cell therapy products for major unmet medical needs in the United States, Japan, and EU regions
This agreement includes upfront and milestone payments with a combined potential value of over $500m and sales royalties.
Vyleesi is the first and only as-needed treatment approved by the Food and Drug Administration (FDA) for premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD)
The acquisition is done through cash consideration, by way of conversion of SAFE (Simple Agreement for Future Equity) investment of US$ 2 Million to Preferred A-1 Shares
JB Chemicals will pay Rs 125 crore to Novartis to license the same drug portfolio for the Indian market
Dr. Reddy's will make a US$ 7.5 million upfront payment to Coya
Final stage in licensing OVM-200 from Oxford Vacmedix in the UK
Digitally enabled drug discovery for oncology with potential to accelerate the delivery of new cancer therapies to patients
European operations' revenue grew 58.4% to Rs 599.7 crore
The drug will be marketed by Sun Pharma under the brand name RYTSTAT
Subscribe To Our Newsletter & Stay Updated
